M1t

Phill said:

yes, my log
http://www.anabolicsteroidforums.co...-PSL-Methyl-1-testosterone-(M1T)-Vitamins-B12

and m1t is not a prohormone

Click to expand...

Phill said:

Androgenic: 100-220
Anabolic: 910-1600
Standard: Methyltestosterone (oral)
Chemical name: 17alpha methyl-17beta-hydroxyandrost-1-ene-3-one

Estrogenic activity: none
Progestin activity: moderate









Methyl-1-testosterone (code-named development SC-11195), also known as 17α-methyl-4,5α-dihydro-δ1-testosterone (17α-methyl-δ1-DHT) or 17α-methyl-5α-androst -1- en-17β-ol-3-one, as well as methyldihydroboldenone, is a synthetic product, an orally active AAS, which has never been marketed as a drug. It is the 17α-methylated derivative of 1-testosterone (DHT-Δ1; dihydroboldenone).


Methyl-1-testosterone differs from the molecule from which it derives (Dihydroboldenone) from:

1) the addition of a methyl group in the C-17 position that protects the hormone during oral administration: this has made the M1T practically immune from the link with SHBG.

2) the introduction of a double bond between the carbon atoms 1 and 2, which helps to stabilize the 3-keto group and increases the anabolic power of the AAS.

Methyl-1-testosterone has an Androgen: Anabolic ratio of 100-220: 910-1600.

Methyl-1-testosterone was first described in 1962. (1) This compound was developed over the years of increased activity in anabolic steroid research, a time when hundreds of different effective anabolic agents were actively studied by pharmaceutical companies. Although Methyl-1-testosterone showed some favorable effects, showing a high level of potency and an acceptable anabolic / androgenic ratio, as most of the synthesized agents during this time period was never actually developed as a drug. Methyl-1-testosteroe, however, was abandoned among the pages of medical literature for about forty years.

Methyl-1-test
Methyl-1-testosterone suddenly re-emerged in 2003, when it was introduced in the OTC (Over-the-Counter) food supplement market in the United States, due to the fact that this molecule was unknown when the 1991 law controlling and regulates anabolic steroids was written, and therefore not present there. The product was introduced to the market by Legal Gear, and soon became very popular due to its high level of effectiveness. It soon became the subject of many generic copies. Methyl-1-testosterone did not last as long as an OTC product in the United States, and soon passed the law that included this compound among the substances subject to control. The law came into force on January 20, 2005, at which point the possession or distribution of this AAS began to involve the same federal penalties as other anabolic steroids. This led to the successful conclusion of the presence in the US market of Methyl-1-testosterone but, nevertheless, the agent is still available for Body Builders via the black market or UK sports supplementation sites.


Although not subject to specific studies, given the 5-alpha-reduced nature of the molecule, it is believed that the Methyl-1-testosteore is not subject to aromatization. It is known, however, that this steroid probably has intrinsic progestin activity. The side effects associated with Progesterone are similar to those of estrogens, including the inhibition of negative feedback of endogenous testosterone production and a higher rate of fluid accumulation. Progestin compounds also increase the stimulatory effect of estrogen on breast tissue. There seems to be a strong synergy between these two hormones, to such an extent that gynecomastia could also occur with the action of progestogens, without excessive levels of estrogen. The use of a SERM, which inhibits the estrogenic component at the receptor level, is often sufficient to mitigate the gynecomastia caused by AAS progestins.


With an androgenic value of 100-220 compared to Methyltestosterone, M1T has possible androgenic side effects with its use. This can include oily skin, acne, increased hairiness, and androgenetic alopecia. Women can experience virilizing effects including deepening of the voice, menstrual irregularity, changes in the structure of the skin, growth of facial hair, and enlargement of the clitoris. Its Androgen / Anabolic ratio clearly in favor of the latter parameter could theoretically make the use of this molecule acceptable for "Hardcore" women. However, one should not forget that Methyl-1-testosterone can exhibit strong androgenic side effects especially with higher doses, and this must be carefully considered.
Note that Methyl-1-testosterone is not affected by the enzyme 5-alpha reductase, so its relative androgenicity is not affected by the concomitant use of finasteride or dutasteride.


As already mentioned, Methyl-l-testosterone is a methylated AAS in C-17. This alteration protects the drug from hepatic deactivation, allowing a greater percentage of the drug to enter the bloodstream after oral administration. As we all know, it is C-17 methylation that makes M1T a hepatotoxic compound. Prolonged exposure or high doses can cause liver damage. In rare cases, liver dysfunction may develop. It is therefore advisable to carry out regular monitoring of liver function and general health during the use of this AAS. Methylated AAS intake in C-17 is commonly limited to 6-8 weeks, in an attempt to avoid excessive liver stress as much as possible. The use of a liver detoxifying supplement such as Liv-52 or Essiale Forte is recommended while taking hepatotoxic AAS.



As is well known, AAS can have deleterious effects on serum cholesterol. This includes a tendency to decrease HDL cholesterol concentrations (good) and an increase in LDL (bad) cholesterol concentrations, which results in an imbalance in the HDL / LDL balance which results in an increased risk of developing arteriosclerosis. The impact related to the intake of an AAS against blood lipids depends on the dose, the route of administration (orally or injectable), the type of steroid (aromatizable or non-aromatizable), and the level of resistance to hepatic metabolism . Although there are no extensive studies in humans, the oral route of administration, the relative high potency, and the poor or non-aromatizable nature of M1T suggest that this agent is extremely prone to negatively alter lipid values, increasing the atherogenic risk. AAS may also adversely affect blood pressure and triglyceride levels, reducing endothelial relaxation, and promoting left ventricular hypertrophy, all of which have potential to increase the risk of cardiovascular disease and myocardial infarction.

To help reduce cardiovascular stress it is advised to maintain an active cardiovascular exercise program and to minimize saturated fat, cholesterol and simple carbohydrate intake at any time during the administration of AAS.
Supplementation with fish oils (4 grams per day) and a Niacin dietary supplement for cholesterol control is also recommended.
All AAS if taken in sufficient doses to promote muscle gain cause a suppression of endogenous Testosterone. Without the intervention with testosterone-stimulating substances, and an adequate PCT, Testosterone levels should return to normal within 1-4 months of drug transfer. Note that prolonged hypogonadotrophic hypogonadism may develop second to steroid abuse, which requires medical intervention.

Also for Methyl-l-testosterone it is recommended to take it away from meals as studies have shown that taking an oral anabolic steroid with food can decrease its bioavailability. (2) This is caused by the fat-soluble nature of hormones steroid, which may allow a part of the drug to dissolve with undigested food fats, reducing absorption from the gastrointestinal tract. For maximum bioavailability, this steroid should be taken on an empty stomach.

Methyl-l-testosterone has never been approved for use in humans. Prescription guidelines are not available. For doping purposes in men the typically effective oral daily dose is in the range of 5-10 mg, taken for no more than 4-6 weeks. A dose of 20 mg is sometimes used, although this increases the likelihood of marked side effects occurring. Most users do not exceed the 10mg / day threshold. A common complaint reported by users of M1T taking the compound alone is lethargy, which may be due, in part, to its low estrogenic component or its relative low androgenicity. Combined with an aromatizable AAS such as Testosterone it usually alleviates this problem.

This agent is generally not recommended for doping in female athletes due to its high tendency to produce virilizing side effects. Despite this, some athletes insert it in their preparations at low dosages, generally remaining at 5mg / day.

The half-life of the M1T is about 5 hours.
No prescription pharmaceutical product containing Methyl-1 testosterone is currently available. In the black market and at UK sports supplementation sites, it is generally produced and sold in the form of capsules or tablets for oral use at different dosages .

Click to expand...

Phill said:

of course, I didn't write it, just copy it and I hope the translation is more or less understandable

Click to expand...

stinkfingerdelux said:

Coulda rolled with it phill. Now I look like a liar lmao

Sent from my SM-G935V using Tapatalk

Click to expand...

Phill said:

Some good dis-information

Click to expand...